As is usual with the Australian market, there has been no...

As is usual with the Australian market, there has been no recognition of the stunning results the above-mentioned European based company announced last week, nor the potential implications for MSB, nor the continuing  evidence of the efficacy of allogenic stem cells. Basically, TIG announced positive Phase 3 efficacy results for its allogenic stem cell treatment for complex perianal fistulas in Crohn's Disease. Whilst this is a European Phase 3 trial, not FDA based, the results are compelling. A point to note is that treatment for fistulas in Crohn's Disease, whilst a lucrative market, is not the key market in the disease.

And again, the gurus running money in Australia seem to be totally ignoring the fact that this surely adds to the attraction of the therapy to Celgene, whose right to exercise their option over MSB's  trial in this space expires in October. I suspect there may be strong interest from other groups were Celgene to opt not to exercise!
Ps TIG is up by over 40% since the announcement.
http://seekingalpha.com/article/3471356-tigenix-achieves-first-ever-success-in-allogeneic-stem-cell-phase-3-trial?source=bloomberg